Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs
Reported by , , and 4 more outlets
Isomorphic Labs raised $5 billion in a Series C co-led by Sequoia Capital and Greenoaks, six months after its $2.1 billion Series B. The company says it will use the funding to develop its AI drug-design platform and move candidates toward clinical trials.
Key points
- Andreessen Horowitz joined the round; existing investors also participated
- The company says its programs have produced positive preclinical results in oncology and immunology
- No human trial or named clinical candidate was disclosed
- Isomorphic did not disclose its valuation
Sources
- BloombergRead ↗Sequoia, Greenoaks Lead Isomorphic Lab’s $5 Billion Funding Round
- The Next WebRead ↗Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design
- Tech.euRead ↗Sequoia and Greenoaks lead massive $5BN Series C funding round in Isomorphic Labs
- TechCrunchRead ↗Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
- The DecoderRead ↗Isomorphic Labs raises $5 billion in its second mega-round within six months
Details
Isomorphic Labs said the round was oversubscribed. Andreessen Horowitz joined as a new investor, while existing backers including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund participated. Alphabet also invested, which the company described as significant; it did not give individual contribution amounts.
The company says it will use the funds to advance its IsoDDE drug-design engine, build biological and bioengineering capabilities, and develop clinical infrastructure. It reported positive preclinical results in oncology and immunology programs, but did not provide supporting data or name the programs. TechCrunch reports that Isomorphic has partnerships with Eli Lilly, Novartis and Johnson & Johnson.
TechCrunch and Tech Times report that Isomorphic did not disclose a valuation; TechCrunch says Bloomberg had reported the company was seeking a valuation of about $50 billion. The Next Web reports that CEO Demis Hassabis said more than 20 programs are underway and that the company is on track with regulatory submissions, but he gave no updated target for starting clinical trials.
Written from coverage as of
Images
- TechCrunch
- The Decoder
- The Next Web
- Tech.eu
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh